Search results for "digestive system"

showing 10 items of 1747 documents

Persistent and recurrent achalasia after Heller myotomy: analysis of different patterns and long-term results of reoperation.

2007

Hypothesis Two groups of patients with inadequate therapeutic success after surgical treatment for achalasia can be identified, patients with type 1 recurrence (early recurrence after technical failure of myotomy or a scarring process requiring remyotomy) and patients with type 2 recurrence (late recurrence with irreversible progression of the disease and development of megaesophagus requiring esophagectomy). Design Prospective study. Setting University-based tertiary care center. Patients One hundred sixty-three patients undergoing surgery for achalasia during 20.3 years. Interventions Conventional remyotomy for type 1 recurrence (group 1) and esophagectomy (transhiatal or transthoracic) f…

MyotomyAdultMaleReoperationmedicine.medical_specialtymedicine.medical_treatmentAchalasiaEsophagusRecurrenceMedicineHumansProspective StudiesTreatment FailureEsophagusReflux esophagitisDigestive System Surgical ProceduresAgedHeller myotomybusiness.industryMegaesophagusMiddle Agedmedicine.diseaseDysphagiaSurgeryEsophageal AchalasiaEsophagectomymedicine.anatomical_structureTreatment OutcomeEsophagectomyEsophagoplastySurgeryFemalemedicine.symptombusinessArchives of surgery (Chicago, Ill. : 1960)
researchProduct

Impact of Minimally Invasive Surgery in the Spectrum of Current Achalasia Treatment Options

2011

Minimally invasive Heller myotomy has evolved the “gold standard” procedure for achalasia in the spectrum of current treatment options. The laparoscopic technique has proved superior to the thoracoscopic approach due to improved visualization of the esophagogastric junction. Operative controversies most recently include the length of the myotomy, especially of its fundic part, with respect to the balance between postoperative persistent dysphagia and development of gastroesophageal reflux, as well as the type of the added antireflux procedure. Perioperative mortality should approach 0%, and favorable long-term results can be achieved in > 90%.

Myotomymedicine.medical_specialtyBotulinum Toxinsmedicine.medical_treatmentAchalasiaCatheterizationPostoperative Complicationsotorhinolaryngologic diseasesHumansMinimally Invasive Surgical ProceduresMedicineEsophagogastric junctionIntraoperative ComplicationsHeller myotomyAnti-Dyskinesia Agentsbusiness.industryThoracoscopyGold standardTreatment optionsRoboticsmedicine.diseaseDysphagiadigestive system diseasesSurgeryEsophageal AchalasiaInvasive surgeryQuality of LifeLaparoscopySurgeryEsophagoscopymedicine.symptombusinessScandinavian Journal of Surgery
researchProduct

Zweizeitige Ösophagusresektion mit ischämischer Präkonditionierung des Schlauchmagens bei dekompensiertem Dolichomegaösophagus im Endstadium der Acha…

2008

Development of a megaesophagus with a sigmoid-shaped distal part in patients with achalasia--even in the course of successful myotomy with reduction of the resting pressure of the lower esophageal sphincter--is often the expression of an irreversible progression of the disease. Management of patients with end-stage achalasia and aperistaltic, dilated "burned-out" esophagus--with or without peptic stenosis--is a therapeutic challenge for gastroenterologists and surgeons. We report on a 37-year-old female patient with decompensated dolichomegaesophagus following multiple endoscopic and operative interventions at the lower and upper esophageal sphincters presenting with severe dysphagia and we…

Myotomymedicine.medical_specialtybusiness.industryPepticmedicine.medical_treatmentGastroenterologyMegaesophagusAchalasiaAnastomosismedicine.diseaseDysphagiadigestive system diseasesSurgeryEsophagectomyotorhinolaryngologic diseasesmedicineIschemic preconditioningmedicine.symptombusinessZeitschrift für Gastroenterologie
researchProduct

Interferon-alpha inhibits hepatitis C virus subgenomic RNA replication by an MxA-independent pathway.

2001

Hepatitis C virus (HCV) persists in the majority of infected individuals and is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Chronic hepatitis C is currently treated with interferon (IFN)-α or with a combination of IFN-α and ribavirin. The availability of an HCV replicon system (Lohmann et al., Science 285, 110–113, 1999) allowed the investigation of the effects of IFN on genuine HCV replication in cultured cells. It is shown here that IFN-α inhibits subgenomic HCV RNA replication in HuH-7 human hepatoma cells. Immunofluorescence, Western blot and Northern blot analysis revealed that levels of both HCV protein and replicon RNA were reduced after treatme…

Myxovirus Resistance ProteinsHepatitis C virusHepacivirusBiologyViral Nonstructural Proteinsmedicine.disease_causeAntiviral Agentschemistry.chemical_compoundInterferonGTP-Binding ProteinsVirologymedicineTumor Cells CulturedHumansRepliconNorthern blotSubgenomic mRNADose-Response Relationship DrugRibavirinvirus diseasesRNAInterferon-alphaProteinsVirologyMolecular biologydigestive system diseasesNS2-3 proteasechemistryRNA ViralRepliconmedicine.drugThe Journal of general virology
researchProduct

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

2020

Background & Aims NAFLD is a growing health concern. The aim of the Fatty Liver Assessment in Germany (FLAG) study was to assess disease burden and provide data on the standard of care from secondary care. Methods The FLAG study is an observational real-world study in patients with NAFLD enrolled at 13 centres across Germany. Severity of disease was assessed by non-invasive surrogate scores and data recorded at baseline and 12 months. Results In this study, 507 patients (mean age 53 years; 47% women) were enrolled. According to fibrosis-4 index, 64%, 26%, and 10% of the patients had no significant fibrosis, indeterminate stage, and advanced fibrosis, respectively. Patients with advanced fib…

NAFLD non-alcoholic fatty liver diseasemedicine.medical_specialtyBMI body mass indexNASH non-alcoholic steatohepatitisLiver fibrosisLSM liver stiffness measurementAST aspartate aminotransferaseLiver diseaseFLAG Fatty Liver Assessment in GermanyNAFLDALT alanine aminotransferaseInternal medicineAPRI aspartate-aminotransferase-to-platelet ratio indexInternal MedicineNAFL non-alcoholic fatty liverImmunology and AllergyMedicineddc:610Co-morbiditieslcsh:RC799-869FIB-4 fibrosis-4Disease burdenHepatologyFAST FibroScan-ASTGGT gamma-glutamyltransferasebusiness.industryFatty liverNASHGastroenterologyReal worldGLP-1 glucagon-like peptide-1T2DM type 2 diabetes mellitusCVE cardiovascular eventmedicine.diseaseMetabolic syndromeCohortlcsh:Diseases of the digestive system. GastroenterologyCAP controlled attenuation parameterSteatohepatitisMetabolic syndromebusinessBody mass indexResearch ArticleCohort studyJHEP Reports
researchProduct

Determining a healthy reference range and factors potentially influencing PRO-C3 – A biomarker of liver fibrosis

2021

Background & Aims Progressive fibrosis has been identified as the major predictor of mortality in patients with non-alcoholic fatty liver disease (NAFLD). Several biomarkers are currently being evaluated for their ability to substitute the liver biopsy as the reference standard. Recent clinical studies in NAFLD/NASH patients support the utility of PRO-C3, a marker of type III collagen formation, as a marker for the degree of fibrosis, disease activity, and effect of treatment. Here we establish the healthy reference range, optimal sample handling conditions for both short- and long-term serum storage, and robustness for the PRO-C3 assay. Methods PRO-C3 was measured in 269 healthy volunteers…

NASH-CRN NASH Clinical Research NetworkBiopsyDiseaseAST aspartate aminotransferaseRC799-869Ethnic groupsGastroenterologyNIMBLE Non-Invasive Biomarkers of Metabolic Liver Disease (consortium)FibrosisImmunology and AllergyBody mass indexmedicine.diagnostic_testFatty liverNAS NAFLD Activity ScoreGastroenterologyDiseases of the digestive system. GastroenterologyHospitalsNPV negative predictive valueLiver biopsyBiomarker (medicine)Research Articlemedicine.medical_specialtyNAFLD non-alcoholic fatty liver diseaseADAM A Disintegrin and MetalloproteasesNASH non-alcoholic steatohepatitisReference rangeReference valuesAUROC area under the receiver operating characteristics curveInternal medicineALT alanine aminotransferaseBiopsyInternal MedicinemedicineHumansFIB-4 fibrosis-4Healthy volunteersHepatologyALP alkaline phosphatasebusiness.industryCLSI Clinical and Laboratory Standards InstituteT2DM type 2 diabetes mellitusELF™ test Enhanced Liver Fibrosis testmedicine.diseaseLITMUS Liver Investigation: Testing Marker Utility in Steatohepatitis (consortium)Collagen type IIIFibrosisPPV positive predictive valueReference standardsbusinessBody mass indexBiomarkersNon-alcoholic fatty liver disease
researchProduct

Cajal–Retzius cells: Update on structural and functional properties of these mystic neurons that bridged the 20th century

2014

Cajal-Retzius cells (CRc) represent a mostly transient neuronal cell type localized in the uppermost layer of the developing neocortex. The observation that CRc are a major source of the extracellular matrix protein reelin, which is essential for the laminar development of the cerebral cortex, attracted the interest in this unique cell type. In this review we will (i) describe the morphological and molecular properties of neocortical CRc, with a special emphasize on the question which markers can be used to identify CRc, (ii) summarize reports that identified the different developmental origins of CRc, (iii) discuss the fate of CRc, including recent evidence for apoptotic cell death and a p…

NeuronsCell typeProgrammed cell deathNeocortexbiologyGeneral NeuroscienceNeocortexMarginal zonedigestive system diseasesReceptors NeurotransmitterCortex (botany)Extracellular matrixmedicine.anatomical_structureCerebral cortexmedicinebiology.proteinAnimalsReelinNerve NetPsychologyneoplasmsNeuroscienceNeuroscience
researchProduct

Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells

2015

Sorafenib (Sor), an effective chemiotherapeutic drug utilized against hepatocellular carcinoma (HOC), robustly interacts with nonionic amphiphilic cyclodextrin (aCD, SC6OH), forming, in aqueous solution, supramolecular complexes that behave as building blocks of highly water-dispersible colloidal nanoassemblies. SC6OH/Sor complex has been characterized by complementary spectroscopic techniques, such as UV-vis, steady-state fluorescence and anisotropy, resonance light scattering and H-1 NMR. The spectroscopic evidences and experiments carried out in the presence of an adamantane derivative, which competes with drug for CD cavity, agree with the entrapment of Sor in aCD, pointing out the role…

NiacinamideErythrocytesPolymers and PlasticsCell SurvivalAdamantaneDrug CompoundingSupramolecular chemistryBioengineeringNanotechnologyAdamantaneAntineoplastic AgentsBinding CompetitiveHemolysisAmphiphilic Cyclodextrins; Nanoparticles; Sorafenib; HCC cellsHCC cellsBiomaterialschemistry.chemical_compoundSurface-Active AgentsIn vivoCell Line TumorAmphiphileMaterials ChemistryHumanschemistry.chemical_classificationCyclodextrinsAqueous solutionCyclodextrinPhenylurea CompoundsSorafenibFluorescenceCombinatorial chemistrydigestive system diseasesNanostructuresBINDING INTERACTION THERAPY PHARMACOKINETICS BIOAVAILABILITY NANOPARTICLESDrug LiberationKineticsnanoassembliecyclodextrinchemistryDelayed-Action PreparationsProton NMRHepatocytes
researchProduct

Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?

2013

Cancer is a prevalent disease in the elderly population and hepatocellular carcinoma (HCC) is a major health problem among all tumors. Curative treatments for early-stage include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib, classified as non-curative treatments, can improve survival for patients with intermediate and advanced tumors, respectively. Even if the incidence of HCC progressively increases with advanced age in all populations, reaching a peak at 70 years, few reports concerning correct management of HCC in elderly patients exist. Moreover, data from large randomized controlled trials (RCT) poorly reflect the elde…

NiacinamideOncologySorafenibmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentAntineoplastic AgentsDiseaseLiver transplantationSystemic therapylaw.inventionRandomized controlled triallawInternal medicinemedicineHumansPharmacology (medical)HCCAgedbusiness.industryPhenylurea CompoundsIncidence (epidemiology)Liver NeoplasmsAge FactorsCancerSorafenibmedicine.diseasedigestive system diseasesOncologyHepatocellular carcinomabusinessmedicine.drugExpert Review of Anticancer Therapy
researchProduct

Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions

2013

The intermediate stage of hepatocellular carcinoma (HCC) comprises a highly heterogeneous patient population and therefore poses unique challenges for therapeutic management, different from the early and advanced stages. Patients classified as having intermediate HCC by the Barcelona Clinic Liver Cancer (BCLC) staging system present with varying tumor burden and liver function. Transarterial chemoembolization (TACE) is currently recommended as the standard of care in this setting, but there is considerable variation in the clinical benefit patients derive from this treatment.In April 2012, a panel of experts convened to discuss unresolved issues surrounding the application of current guidel…

NiacinamideOncologymedicine.medical_specialtyCarcinoma HepatocellularStandard of careTumor burdenAntineoplastic AgentsGastroenterologyAntineoplastic AgentInternal medicinemedicineHumansChemoembolization TherapeuticStaging systemHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsAdvanced stageSorafenibmedicine.diseasedigestive system diseasesLiver NeoplasmHepatocellular carcinomaLiver functionTreatment decision makingLiver cancerbusinessHumanSeminars in Liver Disease
researchProduct